Belite Bio (BLTE) to Release Quarterly Earnings on Monday

Belite Bio (NASDAQ:BLTE) is expected to post its Q3 2025 results after the market closes on Monday, November 10th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Monday, November 10, 2025 at 4:30 PM ET.

Belite Bio (NASDAQ:BLTE) last posted its earnings results on Monday, August 11th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.03). During the same period in the previous year, the business earned ($0.31) EPS. On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Belite Bio Stock Performance

BLTE opened at $113.19 on Friday. The company has a market cap of $3.60 billion, a PE ratio of -73.03 and a beta of -1.42. The stock has a 50-day moving average of $80.95 and a 200-day moving average of $69.10. Belite Bio has a 52-week low of $49.00 and a 52-week high of $117.89.

Analyst Ratings Changes

BLTE has been the subject of a number of recent analyst reports. Zacks Research upgraded shares of Belite Bio from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 16th. HC Wainwright dropped their target price on shares of Belite Bio from $100.00 to $98.00 and set a “buy” rating on the stock in a research report on Monday, September 15th. Benchmark upped their target price on shares of Belite Bio from $80.00 to $132.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Wall Street Zen upgraded shares of Belite Bio from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Belite Bio in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Belite Bio currently has an average rating of “Moderate Buy” and an average price target of $113.33.

Hedge Funds Weigh In On Belite Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BLTE. JPMorgan Chase & Co. increased its holdings in shares of Belite Bio by 45.2% during the third quarter. JPMorgan Chase & Co. now owns 9,809 shares of the company’s stock worth $726,000 after buying an additional 3,052 shares in the last quarter. Marshall Wace LLP bought a new stake in Belite Bio during the 2nd quarter worth approximately $547,000. BNP Paribas Financial Markets acquired a new stake in Belite Bio during the 2nd quarter valued at $190,000. Finally, EverSource Wealth Advisors LLC bought a new position in Belite Bio in the 2nd quarter valued at $147,000. 0.53% of the stock is currently owned by institutional investors and hedge funds.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.